Tseng J1, Ebrahimi B2, Johnson T1, Copigneaux C3, Beckman RA3, Gordon MS4. 1MD Anderson Cancer Center Orlando, Orlando, FL; 2Wilshire Oncology Medical Group, Corona, CA; 3Daiichi Sankyo Pharmaceutical Development, Edison, NJ; 4Pinnacle Oncology Hematology, Scottsdale, AZ. “A Phase 1b/2 Trial of U3-1287, a HER3 Inhibitor, In Combination With Erlotinib In Patients (pts) With Advanced NSCLC.” Poster presentation at AACR-NCI-EORTC International Conference 2011.
S. P. Rajurkar, C. A. Presant, G. H. Upadhyaya, L. D. Bosserman, B. Ebrahimi, F. D. Howard, S. W. Kim, R. C. Horns, D. Malouf; Wilshire Oncology Medical Group, Inc., La Verne, CA. “Resource utilization requirements for personalized cancer care translational research and clinical trial (CT) implementation.” Submitted, ASCO Annual Meeting, 2010.
G Upadhyaya, CA Presant, L Bosserman, A Estrella, A Greenburg, A Der, C Yeon, M Vakil, R Horns, and B Ebrahimi. Wilshire Oncology Medical Group, LaVerne, California. “Internet (Int) oncology (Onc) information (Inf) services: access and usage by oncology patients (pt) in 2006: the project for internet patient education (PIPE) program. Submitted, Amer Soc Clin Oncol, 2007.
C.A. Presant, L. Bosserman, C. Kelley, T. Young, M. Vakil, R. Horns, G. Upadhyaya, B. Ebrahimi, C. Yeon, F. Howard and A. Rios. Wilshire Oncology Medical Group, LaVerne, California. “Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): frequency and characterization in community based clinical practice.” Proc Amer Soc Clin Onc and Poster Presentation, 2006.
Cynthia L. Martel, MD, PhD, Cary A. Presant, MD, FACP, Ben Ebrahimi, MD, Gargi Upadhyaya, MD, Mayank Vakil, MD, Christina Yeon, MD, Linda D. Bosserman, MD, FACP, and Richard Horns, MD. “Bevacizumab-related toxicities: association of hypertension and proteinuria.” Community Oncology 3.2:90-93, 2006.
Bosserman LD, Horns RC, Presant CA, Vakil MJ, Upadhyaya GH, Martel CL, Ebrahimi B, Yeon CH. “Development and Implementation of Effective Quality Guidelines in Community Cancer Centers: The Cancer Quality Program (CQP).” Proc Amer Soc Clin Oncol 24, 2005.
Horns RC, Bosserman LD, Presant CA, Vakil MJ, Upadhyaya GH, Martel CL, Ebrahimi B, Yeon CH. “Increasing Accrual to Clinical Trials in Community Cancer Centers: A Successful Method Using Electronic Medical Records.” Proc Amer Soc Clin Oncol 24, 2005.
Ebrahimi B, Martel CL, Horns RC, Upadhyaya GH, Vakil MJ, Yeon CH, Bosserman LD and Presant CA. “Heterogeneous Monitoring for and Management of Bevacizumab (BE) Toxicity (T): Development of Standardized Guidelines for Monitoring (mon) and Treatment (tre) of Bevacizumab Toxicity Syndrome (BETS).” Proc Amer Soc Clin Oncol 24, 2005.
Martel CL, Ebrahimi B, Horns RC, Upadhyaya GH, Vakil MJ, Yeon CH, Bosserman LD, and Presant CA. “Incidence of Bevacizumab-Related Toxicities: Association of Hypertension and Proteinuria, the Bevacizumab Toxicity Syndrome (BETS).” Proc Amer Soc Clin Oncol 24, 2005.
Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. “Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.” Cancer 101.12:2727-2736, 2004.
Ebrahimi B, Phan A, Yao JC, Mansfield PF, Pisters PW, Feig BW, Ajani JA. “Phase II clinical trial of Rubitecan against advanced gastric adenocarcinoma.” Poster presentation at ASCO 2002.